Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug entities : Sutro biopharma, inc. save search
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.53 690K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.82 1.26% 170K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $5.039 7.67% 270K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $170.2 1.38% 2M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.37 0.63% 2.4M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.405 2.34% 850K
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-10-19 (Crawled : 12:30) - globenewswire.com
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: -0.57%
H: 1.09%
C: 0.98%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: 1.4%
H: 0.53%
C: -0.81%
PCVX | $61.98 0.62% 240K
|
Health Technology
|
| O: 0.24%
H: 2.54%
C: 0.78%
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -6.27%
vax-31 fda drug disease pneumococcal clearance application
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
Published: 2023-04-18 (Crawled : 18:00) - globenewswire.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 0.21%
H: 0.43%
C: -3.84%
stro-003 drug antibody biopharma preclinical meeting
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: -3.64%
H: 3.09%
C: 1.33%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: -1.68%
H: 1.12%
C: -0.58%
PCVX | $61.98 0.62% 240K
|
Health Technology
|
| O: -0.93%
H: 1.96%
C: 0.55%
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: -1.13%
H: 5.37%
C: -0.98%
vax-24 fda clearance drug disease application pneumococcal
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Published: 2022-06-27 (Crawled : 00:00) - globenewswire.com
ALPMF | News | $9.75 200
|
Health Technology
|
| O: 5.56%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 690K
|
Manufacturing
|
| O: 1.88%
H: 0.0%
C: -0.68%
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 15.01%
H: 14.86%
C: 5.02%
collaboration drug
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 17:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: -0.93%
H: 1.99%
C: -1.05%
stro-002 biopharma drug antibody
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
Published: 2022-03-30 (Crawled : 21:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 0.61%
H: 5.49%
C: 0.37%
biopharma drug antibody
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: 2.64%
H: 0.0%
C: -0.39%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: -0.99%
H: 0.0%
C: -1.16%
PCVX | $61.98 0.62% 240K
|
Health Technology
|
| O: 4.14%
H: 2.57%
C: -1.0%
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: -20.18%
H: 0.0%
C: -9.63%
vax-24 new drug fda clearance application drug disease fda clearance pneumococcal
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
Published: 2021-12-27 (Crawled : 12:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 5.05%
H: 2.02%
C: -2.67%
stro-002 treatment biopharma expansion drug ovarian cancer cancer antibody
Bill Newell, CEO Interviewed by Peter Hofland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
Published: 2021-06-24 (Crawled : 17:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 1.24%
H: 3.19%
C: 2.02%
antibody drug ceo
Bill Newell, CEO Interviewed by Peter Holland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
Published: 2021-06-24 (Crawled : 16:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 1.24%
H: 3.19%
C: 2.02%
antibody drug ceo
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
Published: 2021-06-01 (Crawled : 11:00) - sutrobio.com
STRO | $3.815 1.19% 410K
|
Health Technology
|
| O: 0.7%
H: 5.28%
C: -3.52%
biopharma collaboration antibody drug milestone germany
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.